Herantis Pharma
1.97 EUR
-2.48 %
4,445 following
HRTIS
First North Finland
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Investor consensus
Valuation
Income statement
Quarterly estimates
Valuation
P/E (adj.)
Median 2020-2024
EV/EBIT (adj.)
Median 2020-2024
Dividend yield
Median 2020-2024
P/B
Median 2020-2024
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025e | 2026e | 2027e | 2028e | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Share price (EUR) | 5.23 | 7.37 | 4.15 | 2.40 | 1.65 | 1.58 | 1.52 | 1.97 | 1.97 | 1.97 | 1.97 |
| Shares | 9.8 | 11.1 | 16.9 | 20.2 | 20.2 | 24.1 | 24.1 | 24.1 | 24.1 | ||
| Market cap | 40.5 | 26.6 | 27.9 | 31.9 | 30.6 | 47.5 | 47.5 | 47.5 | 47.5 | ||
| Enterprise value | 34.4 | 26.4 | 26.5 | 25.4 | 28.5 | 49.0 | 55.0 | 61.6 | 69.5 | ||
| EV/S | - | - | 8,593.4 | 6,606.4 | 6,613.7 | 6,360.3 | 2,854.0 | 4,902.2 | 5,495.4 | 6,156.0 | 6,953.7 |
| EV/EBITDA | - | - | neg. | neg. | neg. | 165.2 | neg. | neg. | neg. | neg. | neg. |
| EV/EBIT (adj.) | - | - | neg. | neg. | neg. | 165.2 | neg. | neg. | neg. | neg. | neg. |
| EV/EBIT | - | - | neg. | neg. | neg. | 165.2 | neg. | neg. | neg. | neg. | neg. |
| P/E (adj.) | - | - | neg. | neg. | neg. | 114.2 | neg. | neg. | neg. | neg. | neg. |
| P/E | - | - | neg. | neg. | neg. | 114.2 | neg. | neg. | neg. | neg. | neg. |
| P/B | - | - | 5.3 | neg. | neg. | 6.8 | neg. | neg. | neg. | neg. | neg. |
| P/S | - | - | 10,122.9 | 6,662.4 | 6,976.2 | 7,963.6 | 3,064.5 | 4,746.7 | 4,746.7 | 4,746.7 | 4,746.7 |
| Dividend yield | 0.0 % | 0.0 % | 0.0 % | 0.0 % | 0.0 % | 0.0 % | 0.0 % | 0.0 % | 0.0 % | 0.0 % | 0.0 % |
| Equity ratio | 46.2 % | -14.7 % | -1.1 % | 69.9 % | -11.4 % | -47.5 % | -2,894.8 % | -5,537.3 % | -8,727.9 % | ||
| Gearing ratio | -80.6 % | 19.6 % | 2,071.4 % | -136.0 % | 718.4 % | -119.2 % | -103.5 % | -101.8 % | -101.1 % |